Myoglobin Clearance during Continuous Veno-Venous Hemofiltration with or without Dialysis

1998 ◽  
Vol 21 (4) ◽  
pp. 205-209 ◽  
Author(s):  
D. Nicolau ◽  
Y.S. Feng ◽  
A.H.B. Wu ◽  
S.P. Bernstein ◽  
C.H. Nightingale

The management of acute myoglobinuric renal failure, the major complication of rhab-domyolysis, continues to be a treatment dilemma for the clinician as limited therapeutic options are available. Previously, we have demonstrated that continuous arteriovenous hemofiltration (CAVH) is an effective technique for removing myoglobin in an animal model. In the present study, swine were administered four grams of equine myoglobin intravenously and underwent the continuous veno-venous hemofiltration (CVVH) procedure for six hours each. Animals were studied in each of the following groups: CVVH at a pump rate 100 ml/minute, CVVH at a pump rate 200 ml/minute and CVVH at a pump rate 100 ml/minute plus dialysis at a dialysate flow rate of one Liter/h. Once the filtering process was initiated there was a rapid and sustained production of ultrafiltrate in all groups. The amount of myoglobin excreted in the ultrafiltrate over the six-hour filtering period was 688, 948 and 570 mg which corresponded to 17, 24 and 14 percent of the administered dose, respectively, for the three treatments. In comparison to previous CAVH experiments, CVVH removed more circulating myoglobin and the addition of the dialysis component did not appear to improve removal. Based on these findings, it appears that the CVVH hemofiltration system is a viable option for the removal of systemic myoglobin.

1996 ◽  
Vol 19 (10) ◽  
pp. 578-581 ◽  
Author(s):  
D.P. Nicolau ◽  
Y.J. Feng ◽  
A.H.B. Wu ◽  
S.P. Bernstein ◽  
C.H. Nightingale

Rhabdomyolysis is characterized by extensive damage of striated muscle, while the major complication of this disease is the development of acute myoglobinuric renal failure. Although first described more than five decades ago very little has changed with regard to the management of this entity as conventional hemodialysis has not been shown to effect myoglobin elimination. However, continuous arteriovenous hemofiltration (CAVH) offers an alternative to conventional hemodialysis as this procedure is more effective particularly for removing larger molecular weight substances such as myoglobin. We studied the effect of CAVH on myoglobin clearance in an animal model of acute myoglobinuric renal failure. Swine (n=6) were given 4 grams of equine myoglobin intravenously and underwent the CAVH procedure for six hours each. Once the filtering process was initiated there was a rapid and sustained production of ultrafiltrate. The clearance of myoglobin via the hemofilter was 2.05 ± 1.48 L/day. The amount of myoglobin excreted in the ultrafiltrate over the six hour filtering period was 410 ± 234 mg which accounts for 10.27 ± 5.85 percent of the administered dose. Based on these findings, it appears that the hemofiltration system is a viable option for the removal of myoglobin from the systemic circulation.


1994 ◽  
Vol 23 (4) ◽  
pp. 591-596 ◽  
Author(s):  
Vincent Pichette ◽  
Martine Leblanc ◽  
Alain Bonnardeaux ◽  
Denis Ouimet ◽  
David Geadah ◽  
...  

2018 ◽  
Vol 46 (4) ◽  
pp. 279-285 ◽  
Author(s):  
Maxime Leclerc ◽  
Clémence Bechade ◽  
Patrick Henri ◽  
Elie Zagdoun ◽  
Erick Cardineau ◽  
...  

We conducted a prospective study to assess the impact of the blood pump flow rate (BFR) on the dialysis dose with a low dialysate flow rate. Seventeen patients were observed for 3 short hemodialysis sessions in which only the BFR was altered (300,350 and 450 mL/min). Kt/V urea increased from 0.54 ± 0.10 to 0.58 ± 0.08 and 0.61 ± 0.09 for BFR of 300, 400 and 450 mL/min. For the same BFR variations, the reduction ratio (RR) of β2microglobulin increased from 0.40 ± 0.07 to 0.45 ± 0.06 and 0.48 ± 0.06 and the RR phosphorus increased from 0.46 ± 0.1 to 0.48 ± 0.08 and 0.49 ± 0.07. In bivariate analysis accounting for repeated observations, an increasing BFR resulted in an increase in spKt/V (0.048 per 100 mL/min increment in BPR [p < 0.05, 95% CI (0.03–0.06)]) and an increase in the RR β2m (5% per 100 mL/min increment in BPR [p < 0.05, 95% CI (0.03–0.07)]). An increasing BFR with low dialysate improves the removal of urea and β2m but with a potentially limited clinical impact.


1997 ◽  
Vol 20 (8) ◽  
pp. 422-427 ◽  
Author(s):  
D.S.C. Raj ◽  
S. Tobe ◽  
C. Saiphoo ◽  
M.A. Manuel

Urea kinetics is now widely used to determine the adequacy of dialysis. Several simplified formulae are currently in use but only a few have been accepted into clinical practice because of their simplicity and ease of calculation. A recent analysis of these formulae showed that for the same set of blood urea values the calculated Kt/V can range from 1.0 to 1.5. We have developed a new dialysate-based method (2DSM) to estimate the urea kinetic parameters using dialysate and blood samples taken at the beginning and at the end of dialysis. The total urea removed (TUR) was calculated from the geometric mean of the two dialysate samples, dialysate flow rate and the duration of dialysis. The Watson formula was used to determine the volume of distribution of urea. A comparison of the 2DSM and the direct dialysate quantification (DDQ) method showed the following results (mean ± sd, n = 52): for total urea removal (TUR) 697 ± 32 vs 722 ± 37 mmol (p = 0.6, r2 = 0.928, y = 101 + 0.83 ×, mean difference 25 ± 76 mmol, see Bland-Altman plot), dialysate urea concentration (Durea) 5.55 ± 0.25 vs 5.75 ± 0.29 mmol/l (p = 0.6, r2 = 0.928, y = 0.8 + 0.82 x, mean difference 0.2 ± 0.6 mmol, see Bland-Altman plot), dialyser clearance (K) 232 ± 4.4 vs 235 ± 5.6 ml/min (p - 0.54), Kt/V 1.42 ± 0.04 vs 1.51 ± 0.04 (p = 0.21), volume of distribution of urea (Vd) 40.14 ± 1.04 vs 38.74 ± 1.2 L, (p = 0.38), and PCR 64.6 ± 2.6 vs 68.1 ± 3.1 g/day. We have developed a simple method of determining dialysate-based urea kinetics which requires two dialysate samples, one at the beginning and one at the end of dialysis and a blood sample at the midpoint of dialysis. TUR can be calculated using the dialysate flow rate and the dialysis duration and once this is known all the other kinetic parameters can be calculated.


1996 ◽  
Vol 16 (1_suppl) ◽  
pp. 167-171 ◽  
Author(s):  
Pierre Yves Durand ◽  
Philippe Freida ◽  
Belkacem Issad ◽  
Jacques Chanliau

This paper summarizes the basis of prescription for automated peritoneal dialysis (APD) established during a French national conference on APD. Clinical results and literature data show that peritoneal clearances are closely determined by peritoneal permeability and hourly dialysate flow rate, independently of dwell time or number of cycles. With APD, peritoneal creatinine clearance increases according to the hourly dialysate flow rate to a maximum (plateau), then decreases because of the multiplication of the drain-fill times. The hourly dialysate flow giving the maximum peritoneal creatinine clearance is defined as the “maximal effective dialysate flow” (MEDF). MEDF is higher for high peritoneal permeabilities: MEDF is 1.8 and 4.2 L/hr with nocturnal tidal peritoneal dialysis (TPD) for a 4-hr creatinine dialysate-to-plasma ratio (DIP) of 0.50 and 0.80, respectively. With nightly intermittent peritoneal dialysis (NIPD), MEDF is 1.6 and 2.3 Llhr for a DIP of 0.50 and 0.78, respectively. Under these conditions, tidal modalities can only be considered as a way to increase the MEDF. Using the MEDF concept for an identical APD session duration, the maximal weekly normalized peritoneal creatinine clearance can vary by 340% when 4hr DIP varies from 0.41 to 0.78. APD is not recommended when 4-hr creatinine DIP is lower than 0.50. However, the limits of this technique may be reached at higher peritoneal permeabilities in anurics because of the duration of sessions andlor the additional exchanges required by these patients.


Sign in / Sign up

Export Citation Format

Share Document